Skip to content

Study · Not a test of the peptide alone · 2025

4 results

[The possibility of using neurotropic therapy in patients with persistent postural-perceptual dizziness].

Ivonina NA, Petrov KB

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2025

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

  1. 01HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome

    In patients with persistent postural-perceptual dizziness, vestibular balance improved across treatment groups, especially with complex therapy including Cortexin and Recognan.

    In plain wordsIn patients with persistent dizziness, balance improved across all groups versus pretreatment, especially during complex therapy including Cortexin and Recognan.

    Outcome
    IncreaseVestibular balance
    Study

    n = 60

    Comparator
    pretreatment
    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    The second study of patients showed a significant improvement in vestibular balance, a decrease in anxiety and sleep disorders, especially in patients receiving complex therapy.
    5 context sentences
    Summary · context
    60 patients with PPPD were included in the observational study.
    Summary · context
    Patients in the study group received escitalopram at a dose of 10 mg in basic therapy for 6 months.
    Summary · context
    After 2 weeks from the start of basic therapy, the patients were divided into 3 groups of 20 patients each.
    Summary · context
    Patients of the 1st group were prescribed Cortexin 10 mg intramuscularly, 1 time per day for 10 days, the 2nd group - Cortexin 10 mg intramuscularly, 1 time per day for 10 days, and the drug Recognan 1000 mg 1 sachet 1 time per day for 10 days.
    Summary · context
    Patients of the 3d group received basic therapy Escitalopram 10 mg once a day.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

  2. 02HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome

    In patients with persistent postural-perceptual dizziness, anxiety decreased across treatment groups, especially with complex therapy including Cortexin and Recognan.

    In plain wordsIn patients with persistent dizziness, anxiety decreased across all groups versus pretreatment, especially during complex therapy including Cortexin and Recognan.

    Outcome
    DecreaseAnxiety
    Study

    n = 60

    Comparator
    pretreatment
    Outcome group
    Anxiety and mood · Mental health and mood

    Source sentences

    Summary
    The second study of patients showed a significant improvement in vestibular balance, a decrease in anxiety and sleep disorders, especially in patients receiving complex therapy.
    5 context sentences
    Summary · context
    60 patients with PPPD were included in the observational study.
    Summary · context
    Patients in the study group received escitalopram at a dose of 10 mg in basic therapy for 6 months.
    Summary · context
    After 2 weeks from the start of basic therapy, the patients were divided into 3 groups of 20 patients each.
    Summary · context
    Patients of the 1st group were prescribed Cortexin 10 mg intramuscularly, 1 time per day for 10 days, the 2nd group - Cortexin 10 mg intramuscularly, 1 time per day for 10 days, and the drug Recognan 1000 mg 1 sachet 1 time per day for 10 days.
    Summary · context
    Patients of the 3d group received basic therapy Escitalopram 10 mg once a day.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

  3. 03HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome

    In patients with persistent postural-perceptual dizziness, sleep disorders decreased across treatment groups, especially with complex therapy including Cortexin and Recognan.

    In plain wordsIn patients with persistent dizziness, sleep problems decreased across all groups versus pretreatment, especially during complex therapy including Cortexin and Recognan.

    Outcome
    DecreaseSleep disorders
    Study

    n = 60

    Comparator
    pretreatment
    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The second study of patients showed a significant improvement in vestibular balance, a decrease in anxiety and sleep disorders, especially in patients receiving complex therapy.
    5 context sentences
    Summary · context
    60 patients with PPPD were included in the observational study.
    Summary · context
    Patients in the study group received escitalopram at a dose of 10 mg in basic therapy for 6 months.
    Summary · context
    After 2 weeks from the start of basic therapy, the patients were divided into 3 groups of 20 patients each.
    Summary · context
    Patients of the 1st group were prescribed Cortexin 10 mg intramuscularly, 1 time per day for 10 days, the 2nd group - Cortexin 10 mg intramuscularly, 1 time per day for 10 days, and the drug Recognan 1000 mg 1 sachet 1 time per day for 10 days.
    Summary · context
    Patients of the 3d group received basic therapy Escitalopram 10 mg once a day.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

  4. 04HumanNot a test of Cortexin (cortical polypeptide complex) aloneObservational studyEfficacy outcome

    In patients with persistent dizziness, Cortexin plus Recognan on escitalopram was associated with positive multidomain changes at the third assessment.

    In plain wordsIn patients with persistent dizziness, Cortexin plus Recognan on escitalopram was linked to improved measures at the third assessment versus pretreatment.

    Outcome
    Direction not reportedLate multidomain symptom changes
    Study

    n = 20

    Comparator
    pretreatment
    Outcome group
    Overall treatment effect · Nervous system and cognition

    Source sentences

    Summary
    In the third test, patients receiving Cortexin and Recognan showed statistically significant positive changes in almost all indicators: VSS-ST-V and VSS-ST-A subscales (average score 27.15±2.83), insomnia, and ASI-3.
    5 context sentences
    Summary · context
    60 patients with PPPD were included in the observational study.
    Summary · context
    Patients in the study group received escitalopram at a dose of 10 mg in basic therapy for 6 months.
    Summary · context
    After 2 weeks from the start of basic therapy, the patients were divided into 3 groups of 20 patients each.
    Summary · context
    Patients of the 1st group were prescribed Cortexin 10 mg intramuscularly, 1 time per day for 10 days, the 2nd group - Cortexin 10 mg intramuscularly, 1 time per day for 10 days, and the drug Recognan 1000 mg 1 sachet 1 time per day for 10 days.
    Summary · context
    Patients of the 3d group received basic therapy Escitalopram 10 mg once a day.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.